• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy - Product Image

Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy

  • ID: 2306023
  • November 2012
  • 137 Pages
  • GBI Research

FEATURED COMPANIES

  • Bayer
  • Eli-Lilly
  • Merck
  • Pfizer
  • Roche
  • Warner Chilcott
  • MORE

GBI Research, a leading business intelligence provider, has released its latest research, “Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy”, which provides insights into the women’s health therapeutics market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts. It provides an in-depth analysis of the major diseases, and includes coverage of menopause, postmenopausal osteoporosis, endometriosis, infertility, and female contraceptives.

The report provides in-depth analysis of the drivers and barriers that affect the global women’s health market, and analyzes the markets for women’s health disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. The report also analyzes the women’s health therapeutics market in India, China and Australia. Furthermore, the report provides competitive benchmarking for the leading companies READ MORE >

FEATURED COMPANIES

  • Bayer
  • Eli-Lilly
  • Merck
  • Pfizer
  • Roche
  • Warner Chilcott
  • MORE

1.1 List of Tables
1.2 List of Figures

2 Women’s Health Therapeutics Market to 2018 - Introduction
2.1 Overview

3 Women’s Health Therapeutics Market to 2018 - Market Overview
3.1 Introduction
3.2 Revenue Forecasts for the Women’s Health Therapeutics Market
3.2.1 Revenues
3.2.2 Annual Cost of Therapy
3.2.3 Branded and Generic Market Share
3.3 Treatment Usage Patterns
3.4 Drivers and Barriers for the Women’s Health Therapeutics Market
3.4.1 Drivers for the Women’s Health Therapeutics Market
3.4.2 Barriers for the Women’s Health Therapeutics Market

4 Women’s Health Therapeutics Market to 2018 - Geographical Landscape
4.1 The US
4.1.1 Revenue
4.1.2 Annual Cost of Therapy
4.1.3 Treatment Usage Pattern
4.2 Top Five Countries of Europe
4.2.1 Revenue
4.2.2 Annual Cost of Therapy
4.2.3 Treatment Usage Pattern
4.3 Japan
4.3.1 Revenue
4.3.2 Annual Cost of Therapy
4.3.3 Treatment Usage Pattern
4.4 Women’s Health Therapeutics Market, Australia - Overview
4.4.1 Epidemiology
4.4.2 Clinical Trials
4.4.3 Drivers and Restraints
4.5 Women’s Health Therapeutics Market, India - Overview
4.5.1 Epidemiology
4.5.2 Clinical Trials
4.5.3 Drivers and Restraints
4.6 Women’s Health Therapeutics Market, China - Overview
4.6.1 Epidemiology
4.6.2 Clinical Trials
4.6.3 Drivers and Restraints

5 Women’s Health Therapeutics Market to 2018 - Therapeutic Landscape
5.1 Menopause
5.1.1 Introduction
5.1.2 Revenues
5.1.3 Branded and Generic Market Share
5.1.4 Annual Cost of Therapy
5.1.5 Treatment Usage Patterns
5.1.6 Major Marketed Products in the Menopause Therapeutics Market
5.1.7 Drivers for the Menopause Therapeutics Market
5.1.8 Barriers for the Menopause Therapeutics Market
5.2 Postmenopausal Osteoporosis
5.2.1 Introduction
5.2.2 Revenues
5.2.3 Branded versus Generic Market Share
5.2.4 Annual Cost of Therapy
5.2.5 Treatment Usage Patterns
5.2.6 Treatment Flow Algorithm
5.2.7 Major Marketed Drugs in the Postmenopausal Osteoporosis Market
5.2.8 Drivers for the Postmenopausal Osteoporosis Market
5.2.9 Barriers for the Postmenopausal Osteoporosis Market
5.3 Endometriosis
5.3.1 Introduction
5.3.2 Revenues
5.3.3 Branded and Generic Market Share
5.3.4 Annual Cost of Therapy
5.3.5 Treatment Usage Patterns
5.3.6 Treatment Flow Algorithm
5.3.7 Major Marketed Drugs for Endometriosis
5.3.8 Drivers for the Endometriosis Therapeutics Market
5.3.9 Barriers for the Endometriosis Therapeutics Market
5.4 Infertility
5.4.1 Introduction
5.4.2 Revenues
5.4.3 Branded and Generic Market Share
5.4.4 Annual Cost of Therapy
5.4.5 Treatment Usage Patterns
5.4.6 Treatment Flow Algorithm
5.4.7 Major Marketed Drugs in the Infertility Therapeutics Market
5.4.8 Drivers for the Infertility Therapeutics Market
5.4.9 Barriers for the Infertility Therapeutics Market
5.5 Female Contraceptives
5.5.1 Introduction
5.5.2 Revenues
5.5.3 Share of Prescription and OTC Contraceptives
5.5.4 Annual Cost of Usage
5.5.5 Treatment Usage Patterns
5.5.6 Major Marketed Products in the Female Contraceptives Market
5.5.7 Drivers for the Female Contraceptives Market
5.5.8 Barriers for the Female Contraceptives Market

6 Women’s Health Therapeutics Market to 2018 - Pipeline Analysis
6.1 Overview
6.2 Research and Development Pipeline - Menopause
6.2.1 Overview
6.3 Research and Development Pipeline - Postmenopausal Osteoporosis
6.3.1 Overview
6.4 Research and Development Pipeline - Endometriosis
6.4.1 Overview
6.5 Research and Development Pipeline - Infertility
6.5.1 Overview
6.6 Research and Development Pipeline - Female Sexual Dysfunction
6.6.1 Overview
6.7 Research and Development Pipeline - Contraceptives
6.7.1 Overview
6.8 Profiles of Promising Drugs in the Women’s Health Therapeutics Market
6.8.1 Menerba
6.8.2 Odanacatib
6.8.3 Elagolix
6.8.4 Libigel
6.8.5 Femprox
6.8.6 MK 8962
6.8.7 Zoely
6.8.8 AMG 785

7 Women’s Health Therapeutics Market to 2018 - Competitive Landscape
7.1 Market Share Analysis: Women’s Health Therapeutics Market
7.2 Competitive Profiling
7.2.1 Warner Chilcott
7.2.2 Pfizer
7.2.3 Eli-Lilly
7.2.4 Merck
7.2.5 Roche
7.2.6 Bayer

8 Women’s Health Therapeutics Market to 2018 - Strategic Consolidations
8.1 Overview
8.2 Deals by Year
8.3 Deals by Type
8.4 Deals by Value
8.5 Mergers and Acquisitions
8.5.1 Major M&A Deals
8.6 Licensing Agreements
8.6.1 Major Licensing Agreements
8.7 Partnerships
8.7.1 Major Partnership Deals

9 Women’s Health Therapeutics Market to 2018 - Appendix
9.1 Abbreviations
9.2 Market Definitions
9.3 Bibliography
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.4.4 Expert Panel Validation
9.4.5 Section-wise Research Methodology
9.5 Therapeutic Landscape
9.5.2 Market Size by Geography
9.6 Geographical Landscape
9.7 Pipeline Analysis
9.8 Competitive Landscape
9.9 Strategic Consolidations
9.10 Contact Us
9.11 Disclaimer

1.1 List of Tables
Table 1: Women’s Health Therapeutics Market, Global, Revenue ($bn), 2003-2011
Table 2: Women’s Health Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
Table 3: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
Table 4: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 5: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
Table 6: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 7: Women’s Health Therapeutics Market, The US, Revenue ($bn), 2003-2011
Table 8: Women’s Health Therapeutics Market, The US, Revenue Forecasts ($bn), 2011-2018
Table 9: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2011
Table 10: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2018
Table 11: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2011
Table 12: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2011-2018
Table 13: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue ($m), 2003-2011
Table 14: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2011-2018
Table 15: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2011
Table 16: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2011-2018
Table 17: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2011
Table 18: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2011-2018
Table 19: Women’s Health Therapeutics Market, Japan, Revenue ($m), 2003-2011
Table 20: Women’s Health Therapeutics Market, Japan, Revenue Forecasts ($m), 2011-2018
Table 21: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2011
Table 22: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018
Table 23: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2011
Table 24: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2011-2018
Table 25: Women’s Health Therapeutics Market, Pipeline Molecules, Australia, 2012
Table 26: Women’s Health Therapeutics Market, Pipeline Molecules, India, 2012
Table 27: Women’s Health Therapeutics Market, Pipeline Molecules, China, 2012
Table 28: Menopause Therapeutics Market, Global, Revenue ($m), 2003-2011
Table 29: Menopause Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
Table 30: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011
Table 31: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2011-2018
Table 32: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
Table 33: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 34: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
Table 35: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 36: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 2003-2011
Table 37: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2011-2018
Table 38: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2011
Table 39: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2011-2018
Table 40: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
Table 41: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 42: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
Table 43: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 44: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Revenues, 2011
Table 45: Endometriosis Therapeutics Market, Global, Revenue ($m), 2003-2011
Table 46: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
Table 47: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011
Table 48: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2011-2018
Table 49: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
Table 50: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 51: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
Table 52: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 53: Infertility Therapeutics Market, Global, Revenue ($m), 2003-2011
Table 54: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2011-2018
Table 55: Infertility Therapeutics Market, Global, Revenue by Geography ($m), 2003-2011
Table 56: Infertility Therapeutics Market, Global, Revenue Forecasts by Geography ($m), 2011-2018
Table 57: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2011
Table 58: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2018
Table 59: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2011
Table 60: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 61: Infertility Therapeutics Market, Major Marketed Drug Revenues ($m), 2011
Table 62: Efficacy Outcome by Treatment Groups in Ovulation Induction for Study FPI FSH 99-03 (One Cycle of Treatment)
Table 63: Efficacy Outcome for IVF Study FPI FSH 2001-01 (One Cycle of Treatment)
Table 64: Contraceptives Market, Global, Revenue ($bn), 2003-2011
Table 65: Contraceptives Market, Global, Revenue Forecasts ($bn), 2011-2018
Table 66: Contraceptives Market, Global, Revenue by Type ($m), 2003-2011
Table 67: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2011-2018
Table 68: Contraceptives Market, Global, Revenue by Geographical Segmentation ($m), 2003-2011
Table 69: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2011-2018
Table 70: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2011
Table 71: Contraceptives Market, Global, Annual Cost of Usage ($), 2011-2018
Table 72: Contraceptives Market, Global, Treatment Usage Patterns (million), 2003-2011
Table 73: Contraceptives Market, Global, Treatment Usage Patterns (million), 2011-2018
Table 74: Contraceptives Market, Major Marketed Drug Market Share, 2011
Table 75: Women’s Health Therapeutics Market, Global, Pipeline by Phase (%), 2012
Table 76: Women’s Health Therapeutics Market, Global, Pipeline by Indication (%), 2012
Table 77: Women’s Health Therapeutics Market, Global, Pipeline Analysis, Most Promising Molecules, 2012
Table 78: Women’s Health Therapeutics Market, Warner Chilcott, Major Marketed Products, 2011
Table 79: Women’s Health Therapeutics Market, Pfizer, Major Marketed Products, 2011
Table 80: Women’s Health Therapeutics Market, Eli Lilly, Major Marketed Products, 2011
Table 81: Women’s Health Therapeutics Market, Merck, Major Marketed Products, 2011
Table 82: Women’s Health Therapeutics Market, Roche, Major Marketed Products, 2011
Table 83: Women’s Health Therapeutics Market, Bayer, Major Marketed Products, 2011
Table 84: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Mergers and Acquisitions, 2010-2012
Table 85: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Licensing Agreements, 2010-2012
Table 86: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Partnerships, 2010-2012

1.2 List of Figures
Figure 1: Women’s Health Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2018
Figure 2: Women’s Health Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
Figure 3: Women’s Health Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 4: Women’s Health Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
Figure 5: Women’s Health Therapeutics Market, Global, Drivers and Barriers
Figure 6: Women’s Health Therapeutics Market, The US, Revenue Forecasts ($bn), 2003-2018
Figure 7: Women’s Health Therapeutics Market, The US, Annual Cost of Therapy ($), 2003-2018
Figure 8: Women’s Health Therapeutics Market, The US, Treatment Usage Patterns (million), 2003-2018
Figure 9: Women’s Health Therapeutics Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2003-2018
Figure 10: Women’s Health Therapeutics Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2003-2018
Figure 11: Women’s Health Therapeutics Market, Top Five Countries of Europe, Treatment Usage Patterns (million), 2003-2018
Figure 12: Women’s Health Therapeutics Market, Japan, Revenue Forecasts ($m), 2003-2018
Figure 13: Women’s Health Therapeutics Market, Japan, Annual Cost of Therapy ($), 2003-2018
Figure 14: Women’s Health Therapeutics Market, Japan, Treatment Usage Patterns (million), 2003-2018
Figure 15: Menopause Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018
Figure 16: Menopause Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018
Figure 17: Menopause Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 18: Menopause Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
Figure 19: Menopause Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
Figure 20: Menopause Therapeutics Market, Global, Drivers and Barriers
Figure 21: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue Forecasts ($bn), 2003-2018
Figure 22: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue by Geographical Segmentation ($m), 2003-2018
Figure 23: Postmenopausal Osteoporosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 24: Postmenopausal Osteoporosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
Figure 25: Postmenopausal Osteoporosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
Figure 26: Postmenopausal Osteoporosis Therapeutics Market, Treatment Flow Algorithm
Figure 27: Postmenopausal Osteoporosis Therapeutics Market, Major Marketed Drug Market Share, 2011
Figure 28: Postmenopausal Osteoporosis Therapeutics Market, Global, Drivers and Barriers
Figure 29: Endometriosis Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018
Figure 30: Endometriosis Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018
Figure 31: Endometriosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 32: Endometriosis Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
Figure 33: Endometriosis Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
Figure 34: Endometriosis Therapeutics Market, Treatment Flow Algorithm
Figure 35: Endometriosis Therapeutics Market, Global, Drivers and Barriers
Figure 36: Infertility Therapeutics Market, Global, Revenue Forecasts ($m), 2003-2018
Figure 37: Infertility Therapeutics Market, Global, Revenue by Geography ($m), 2003-2018
Figure 38: Infertility Therapeutics Market, Global, Branded and Generic Market Share (%), 2011 and 2018
Figure 39: Infertility Therapeutics Market, Global, Annual Cost of Therapy ($), 2003-2018
Figure 40: Infertility Therapeutics Market, Global, Treatment Usage Patterns (million), 2003-2018
Figure 41: Infertility Therapeutics Market, Treatment Flow Algorithm
Figure 42: Infertility Therapeutics Market, Global, Drivers and Barriers
Figure 43: Contraceptives Market, Global, Revenue Forecasts ($bn), 2003-2018
Figure 44: Contraceptives Market, Global, Revenue Forecasts by Type ($m), 2003-2018
Figure 45: Contraceptives Market, Global, Revenue Forecasts by Geographical Segmentation ($m), 2003-2018
Figure 46: Contraceptives Market, Global, Share of Prescription and OTC Contraceptives (%), 2011
Figure 47: Contraceptives Market, Global, Annual Cost of Usage ($), 2003-2018
Figure 48: Contraceptives Market, Global, Treatment Usage Patterns (million), 2003-2018
Figure 49: Contraceptives Market, Major Marketed Drug Market Share, 2011
Figure 50: Contraceptives Market, Global, Drivers and Barriers
Figure 51: Women’s Health Therapeutics Market, Global, Pipeline by Phase (%), 2012
Figure 52: Women’s Health Therapeutics Market, Global, Pipeline by Indication (%), 2012
Figure 53: Menopause Therapeutics Market, Global, Pipeline by Phase (%), 2012
Figure 54: Postmenopausal Osteoporosis Therapeutics Market, Global, Pipeline by Phase (%), 2012
Figure 55: Endometriosis Therapeutics Market, Global, Pipeline by Indication (%), 2012
Figure 56: Infertility Therapeutics Market, Global, Pipeline by Indication (%), 2012
Figure 57: Female Sexual Dysfunction Therapeutics Market, Global, Pipeline by Indication (%), 2012
Figure 58: Female Contraceptives Market, Global, Pipeline by Indication (%), 2012
Figure 59: Women’s Health Therapeutics Market, Global, Market Share of Companies (%), 2011
Figure 60: Women’s Health Therapeutics Market, Warner Chilcott SWOT Analysis, 2012
Figure 61: Women’s Health Therapeutics Market, Pfizer SWOT Analysis, 2012
Figure 62: Women’s Health Therapeutics Market, Eli Lilly SWOT Analysis, 2012
Figure 63: Women’s Health Therapeutics Market, Merck SWOT Analysis, 2012
Figure 64: Women’s Health Therapeutics Market, Roche SWOT Analysis, 2012
Figure 65: Women’s Health Therapeutics Market, Bayer SWOT Analysis, 2012
Figure 66: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Year, 2010-2012
Figure 67: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Type, 2010-2012
Figure 68: Women’s Health Therapeutics Market to 2018, Global, Strategic Consolidations, Deals by Value, 2010-2012
Figure 69: GBI Research Market Forecasting Model

FEATURED COMPANIES

  • Bayer
  • Eli-Lilly
  • Merck
  • Pfizer
  • Roche
  • Warner Chilcott
  • MORE

Demand Grows for Alternative to Hormone Therapy in Menopausal Women

There is room for improvement in the female health disorders market, and this is fuelling pharmaceutical companies to invest in R&D programs, stated a new report by healthcare experts GBI Research.

The new report* states that increased focus is being shown in therapy areas such as menopause, female sexual dysfunction and infertility, as large target markets and unsatisfactory existing treatments make patients a willing target for new treatments.

The ageing population is driving the menopause therapeutics market, as menopausal symptoms often emerge after the age of 50, with indications such as hot flashes affecting up to 85% of menopausal women. As the population grows older, the number of postmenopausal women will increase.

The menopause therapeutics market is currently dominated by hormone therapies with highly questionable safety profiles. Patients as well as physicians are often reluctant to try hormone therapy as the first line treatment for menopausal symptoms and osteoporosis, as a result of studies such as the WHI Memory Study (WHIMS), the Estrogen Replacement and Atherosclerosis (ERA) study, and the Million Women Study, which have all raised concerns over the safety profile of hormone treatment (HT). Results suggested that hormone treatment (HT) was associated with an increased risk of breast cancer, venous thromboembolism and stroke. The availability of alternative options such as lifestyle and diet changes, exercise and home remedies has also damaged the hormone therapy market, as despite the severity of postmenopausal symptoms, a majority of postmenopausal women tend to opt for home remedies and lifestyle changes rather than using hormone therapy.

Aprela is a progesterone-free treatment for menopausal symptoms which combines conjugated estrogens and bazedoxifene. The drug is currently under review by the US FDA for approval, and is predicted to restore the HT market with peak sales of approximately $1 billion after its expected approval next year. Aprela has shown favorable results in initial studies in comparison to other HT therapeutics, with studies suggesting that Aprela may pose fewer risks and milder side effects than Prempro and Premarin, and no evidence of breast tenderness and pain or increased breast cancer rates as compared to Evista. Other studies revealed that Aprela recipients experienced better sleep and diminished hot flashes compared to women who were treated with a placebo. The drug may therefore provide a better line of treatment for postmenopausal women. Once approved, the treatment is expected to compete strongly with medication currently on offer, significantly altering the menopause market dynamics.

Progression is also being made in the treatment of related menopausal conditions. The female sexual dysfunction therapeutics market currently does not have any FDA approved drugs that are comparable to Viagra for males, but there are many promising molecules in the late stage development phase, most of which have demonstrated high safety and efficacy profiles in clinical trials. If these new therapies can cater to the significant unmet need associated with current treatment options for female sexual dysfunction, they can command a price premium and drive the women’s therapy market.

Steps are also being made in the postmenopausal osteoporosis market, with Amgen Inc recently launching first-in-class drug Prolia, and Merck’s cathepsin K inhibitor Odanacatib (MK-0822) also showing promising results.

The women’s health therapeutics market, including treatments for postmenopausal osteoporosis, hormone replacement therapy, infertility, contraceptives and endometriosis, was valued at $18.8 billion in 2011.

- Warner Chilcott
- Pfizer
- Eli-Lilly
- Merck
- Roche
- Bayer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos